Category Archives: Guest Blog

Sunny Outlook for Outsourcing

Early-stage and mid-size bio/pharmaceutical companies have enjoyed an embarrassment of riches over the past 18 months. The window for initial public offerings (IPOs) re-opened, at least for a while. Global bio/pharmaceutical companies continued their frenzied pace of partnering and acquisition activity, and venture capital spiked up as the prospects improved for rich exits. The results […]
Also posted in Global | Tagged , , | Leave a comment

Healthcare Reform in China: A Doubled-Edge Sword for Foreign Firms?

The Chinese market is attractive to foreign investors for many reasons. It is the world’s third largest market for pharmaceuticals with annual sale of US$71 billion.  In fact, it is poised to become the second largest market in 2015 given that its annual growth rate of sales is between 15 and 20%, according to Yanzhong […]
Also posted in Biotech, Emerging Markets, Global, healthcare, Regulatory | Tagged , | Leave a comment

Gain Competitive Advantage: Think Like a Navy SEAL

Pharmaceutical professionals, teams, and organizations can succeed at an elite level by tackling the tough mental challenges of Navy SEAL training, writes Stan Bernard. Victorious warriors win first in their minds, and then go to war. Defeated warriors go to war first and then seek to win. — Sun Tzu, Author of The Art of War (544 BCE-496 BCE) […]
Also posted in Marketing, Op-Ed, Strategy | Tagged , , | 1 Comment

Major Changes to EU Clinical Trials Regulation

Earlier this year, the newly approved EU Clinical Trials regulation (No 536/2014) was published in the Official Journal of the EU (OJEU).  The European Commission (EC) estimates that all the changes could save researchers €800 million (over $1 billion) a year. It replaces the existing EU Clinical Trials Directive (2001/20/EC), which was intended to simplify […]
Also posted in Europe, Global, R&D, Regulatory | Tagged , , , , | Leave a comment

UK’s Controversial Cancer Fund Boosted — But What’s the Long-Term Plan?

By Leela Barham. The English Cancer Drugs Fund (CDF), set up to provide funding for those products that the National Institute for Health and Care Excellence (NICE) has not recommended for use or where their guidance isn’t yet available, remains controversial. Initially penciled for closure in 2014, it is now planned to run to 2016. […]
Also posted in Europe, Op-Ed, pricing | Tagged , , , , , , | Leave a comment
  • Categories

  • Meta